RecruitingNCT06644287

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

Sponsor

Ruijin Hospital

Enrollment

40 participants

Start Date

Oct 15, 2024

Study Type

OBSERVATIONAL

Conditions

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.

Min Age: 6 YearsMax Age: 80 Years

Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma.
Consider immunotherapy or combined immunotherapy based on clinical judgement.
Signed and dated informed consent form.
Commitment to comply with research procedures and co-operation in the implementation of the full research process.
Aged 6-80 years old.

Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
Intestinal perforation, complete intestinal obstruction
Pregnant women and women who may be pregnant, women who are breastfeeding.
Non-compliant person

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06644287